Experimental Compound Helps Burn Fat Without Losing Muscle

Summary 🧬

A research team at the University of California, Berkeley has developed an experimental compound known as TOFA, which helps burn fat and increase metabolic activity without losing muscle. The compound shows improved blood sugar control, reduced triglycerides, and an improvement in fatty liver disease, through the activation of new cellular pathways that differ from traditional GLP-1 drugs designed to reduce appetite.

TOFA combines inhibiting fat production with activating the body’s system to use it as fuel for energy, which could represent a new therapeutic strategy for obesity, diabetes, and fatty liver problems, with future expectations for human studies to assess safety and effectiveness.

Introduction: Current Challenges in Treating Obesity and Diabetes 🩺

Over the past few years, GLP-1 drugs have made a major breakthrough in the treatment of obesity, diabetes, and fatty liver disease. Drugs such as Ozempic, Wegovy, and Mounjaro stimulate weight loss and help control blood glucose levels.

However, these drugs have side effects such as nausea and gastrointestinal disturbances, in addition to muscle loss due to reduced appetite. This may expose some patients to risks of muscle weakness and increased frailty over the long term.

🧪 A New Strategy: Increasing Energy Expenditure Instead of Reducing Calories

In contrast to the approach of reducing food intake, researchers at the University of California, Berkeley chose a different path. This approach aims to raise the metabolic rate and energy expenditure in the body, which helps burn fat without harming muscle mass.

The team concluded that the compound 5-tetradecyloxy-2-furoic acid (TOFA) has the ability to:

• Inhibit fat production, such as cholesterol and triglycerides.
• Activate genes that encourage cells to use fat as an energy source.
• Improve insulin sensitivity and control glucose levels in the blood.

In experiments on mice, TOFA showed fat loss while preserving muscle mass, in addition to reducing signs of fatty liver disease.

🧠 How TOFA Works: Fat Burning Through a Dual Mechanism

TOFA was discovered in the 1970s, and belongs to the class of ACC (Acetyl-CoA Carboxylase) inhibitors that reduce fat production in the body.

But TOFA stands out for its dual ability to:

• Inhibit fat production.
• Activate PPARα and PPARδ receptors, which turn on genes that help the body use fat as an energy source.

As a result, energy expenditure in mice rose by up to 18% without increased physical activity or a rise in body temperature.

TOFA differs from other ACC inhibitors, which usually cause an increase in triglycerides, as this compound does not show a negative effect on triglyceride accumulation, which may reduce potential cardiovascular risks.

🧪 Comparison Experiments: TOFA’s Effectiveness Alone and in Combination

The researchers tested whether TOFA’s effects could be achieved by using two separate drugs: one that inhibits fat production and another that activates energy consumption.

However, the experiment showed that combining these two drugs did not achieve the same improved metabolic health results as TOFA alone, meaning that the compound’s unique properties are important to achieving the desired effect.

Combining TOFA with GLP-1 Drugs

The researchers conducted an experiment combining TOFA with known GLP-1 drugs such as semaglutide and tirzepatide, and observed greater improvements in weight control, glucose levels, insulin, and triglycerides.

This suggests that TOFA could be an effective complement to appetite-suppressing drugs, which may expand treatment options for patients.

🚨 Future Steps: The Need for Human Trials

Despite the promising results in animal models, the researchers explain that the safety and effectiveness of TOFA need to be thoroughly evaluated in clinical trials on humans.

Research teams, supported by the entrepreneurial environment at Berkeley, plan to move to advanced stages with the goal of developing TOFA as a potential therapeutic option.

📝 Conclusion and Scientific Recommendations

TOFA represents a breakthrough in the treatment of obesity and metabolic disorders by:

• Stimulating fat consumption as an energy source without losing muscle.
• Reducing the production of harmful fats such as triglycerides and cholesterol.
• Improving the body’s response to insulin and controlling blood sugar.
• Integrating with other drugs such as GLP-1 to enhance therapeutic outcomes.

These findings highlight the importance of researching multiple metabolic pathways and expanding the development of innovative and safe therapeutic strategies for obesity, diabetes, and fatty liver problems.

📚 Related articles

New Study Reveals the Reasons for Not Adding Bananas to Smoothies and Their Health Effects

2026/09/07

A Surprising Brain Discovery Pushes Scientists to Rethink Movement Disorders

2026/09/07

🧬 A Brief Summary of Enhanced Natural Killer Cells as a New Weapon Against Cancer

2026/09/24